At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
In Brief
A Phase 2 clinical trial evaluating Placebo, Emraclidine 10 mg, and 1 other intervention for Schizophrenia. Completed, enrolled 385 participants across 25 sites in 2 countries.
Detailed Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Study Details
Timeline
Interventions
Matching placebo, oral (tablet), once per day for 6 weeks
Emraclidine 10 mg, oral (tablet), once per day for 6 weeks
Emraclidine 30 mg, oral (tablet), once per day for 6 weeks